cambridge's bluebird bio licenses delivery tech to novartis, gsk
.
.
.
.
the total amount paid out in critical illness claims was £75.19m, with cancer accounting for 74 per cent of claims from women, mainly breast cancer, alongside 51 per cent from men.
.